Abstract

134P A phase I study exploring the safety and tolerability of the small molecule PD-L1 inhibitor INCB099318 in select advanced solid tumors

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Abstract CT129: A multicohort, open-label, phase 2 basket study of the coformulation of vibostolimab with pembrolizumab, with or without other anticancer therapies, in select solid tumors
Iwona Lugowska ... Tanya Keenan
American Journal of Cancer | VOL. 82
Iwona Lugowska, et. al.Iwona Lugowska ... Tanya Keenan
15 Jun 2022
Abstract B057: BMS-986148, an anti-mesothelin antibody-drug conjugate (ADC), alone or in combination with nivolumab demonstrates clinical activity in patients with select advanced solid tumors
Jeffrey Clarke ... Sandip Pravin Patel
Molecular Cancer Therapeutics | VOL. 18
Jeffrey Clarke, et. al.Jeffrey Clarke ... Sandip Pravin Patel
01 Dec 2019
ADPORT-601: First-in-human study of adenosine 2A (A2A) and adenosine 2B (A2B) receptor antagonists in patients with select advanced solid tumors.
Lawrence Fong ... Russell Kent Pachynski
Journal of Clinical Oncology | VOL. 42
Lawrence Fong, et. al.Lawrence Fong ... Russell Kent Pachynski
01 Jun 2024
Abstract OT2-16-01: ONCX-NAV-G201: A phase 2, basket study of navicixizumab monotherapy or in combination with chemotherapy in patients with select advanced solid tumors: Triple-negative breast cancer cohort (trial in progress)
Amelia B Zelnak ... Heinz-Josef Lenz
American Journal of Cancer | VOL. 83
Amelia B Zelnak, et. al.Amelia B Zelnak ... Heinz-Josef Lenz
01 Mar 2023
View more papers

More From: Immuno-Oncology and Technology

Paper Title
Journal
Date
Author
Integrated non-invasive diagnostics for prediction of survival in immunotherapy
Melda Yeghaian ... Stefano Trebeschi
Immuno-Oncology and Technology | VOL. -
Melda Yeghaian, et. al.Melda Yeghaian ... Stefano Trebeschi
01 Jul 2024
Editorial Board
-
Immuno-Oncology and Technology | VOL. 22
--
01 Jun 2024
Tumor-infiltrating lymphocytes and immune-related adverse events in advanced melanoma
Isabella A.J Van Duin ... Karijn P.M Suijkerbuijk
Immuno-Oncology and Technology | VOL. -
Isabella A.J Van Duin, et. al.Isabella A.J Van Duin ... Karijn P.M Suijkerbuijk
01 Jun 2024
Regional and intratumoral adoptive T-cell therapy
Irene Olivera ... Ignacio Melero
Immuno-Oncology and Technology | VOL. -
Irene Olivera, et. al.Irene Olivera ... Ignacio Melero
01 Jun 2024
View more papers